Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Biomarin
Biomarin
Biotech’s key upcoming clinical results
EP Vantage
Tue, 12/20/22 - 10:27 am
clinical trials
Acadia Pharmaceuticals
Argenx
Arrowhead Pharmaceuticals
Biomarin
BioNTech
Daiichi Sankyo
Day One
EQRx
Fate Therapeutics
FibroGen
Gilead Sciences
Idorsia
Immunogen
Intellia Therapeutics
Karuna Therapeutics
Moderna Therapeutics
Regeneron
Roche
Travere Therapeutics
Vaxcyte
BioMarin's hemophilia gene therapy faces further delays over fresh FDA requests
Fierce Biotech
Tue, 11/8/22 - 10:46 am
Biomarin
gene therapy
FDA
hemophilia
Roctavian
Cost watchdog ICER backs multimillion-dollar price tags for BioMarin, CSL hemophilia gene therapies
Fierce Pharma
Thu, 11/3/22 - 11:02 am
ICER
drug pricing
gene therapy
Biomarin
CSL
Bluebird Bio
hemophilia
BioMarin gets FDA decision date for hemophilia gene therapy, but questions on review remain
BioPharma Dive
Thu, 10/13/22 - 11:52 pm
Biomarin
FDA
hemophilia A
gene therapy
Roctavian
BioMarin lays off 120 employees to save $50M a year, with US operations hardest hit
Fierce Biotech
Fri, 10/7/22 - 11:00 am
Biomarin
layoffs
BioMarin Banks on More Robust Data in Hemophilia A Resubmission
BioSpace
Fri, 09/30/22 - 10:59 am
Biomarin
FDA
hemophilia A
valoctocogene roxaparvovec
ICER Deems Hemophilia Gene Therapies Worth the $2.5M Price Tag
BioSpace
Thu, 09/15/22 - 10:14 am
hemophilia
gene therapy
ICER
Biomarin
Chugai
Roche
CSL Behring
BioMarin says PhIII gene therapy study participant's cancer is unrelated to therapy
Endpoints
Mon, 09/12/22 - 11:42 pm
Biomarin
gene therapy
hemophilia A
clinical trials
BioMarin nets conditional approval for valrox in Europe, marking the first hemophilia gene therapy
Endpoints
Thu, 08/25/22 - 10:59 am
Biomarin
hemophilia A
valrox
Europe
gene therapy
Roctavian
BioMarin's hemophilia gene therapy Roctavian wins conditional EU backing amid FDA delay
Fierce Pharma
Mon, 06/27/22 - 10:05 am
Biomarin
Roctavian
EMA
FDA
hemophilia A
valoctocogene roxaparvovec
BioMarin Delays Hemophilia A Therapy Filing as FDA Calls for More Data
BioSpace
Tue, 05/31/22 - 11:57 pm
Biomarin
hemophilia A
FDA
valoctocogene roxaparvovec
BioMarin's Record Q1 Driven by Recently Approved Achondroplasia Therapy
BioSpace
Wed, 04/27/22 - 10:44 pm
Biomarin
earnings
Another phenylketonuria hold, courtesy of Homology
EP Vantage
Tue, 02/22/22 - 10:43 am
Homology Medicines
HMI-102
Biomarin
BMN 307
FDA
clinical trials
clinical hold
PKU
BioMarin says gene therapy hold will endure as FDA questions cancer risk
BioPharma Dive
Sun, 02/20/22 - 11:54 am
Biomarin
FDA
gene therapy
clinical trials
FDA grounds BioMarin gene therapy trial for months with demand for tumor risk data
Fierce Biotech
Fri, 02/18/22 - 10:32 am
Biomarin
FDA
clinical trials
clinical hold
BMN 307
PKU
gene therapy
BioMarin's hemophilia A gene therapy hits goal in phase 3, teeing up FDA filing despite durability doubts
Fierce Biotech
Mon, 01/10/22 - 11:32 am
Biomarin
hemophilia A
gene therapy
valrox
clinical trials
FDA approves first drug for genetic cause of dwarfism
Stat
Fri, 11/19/21 - 11:06 am
Biomarin
FDA
dwarfism
achondroplasia
Voxzogo
BioMarin's new launch Voxzogo could surprise investors and become a blockbuster brand: analyst
Fierce Pharma
Mon, 11/15/21 - 12:24 pm
Biomarin
FDA
Voxzogo
dwarfism
Go or go go? J&J’s cell therapy heads to the FDA
EP Vantage
Fri, 10/29/21 - 10:33 am
JNJ
cilta-cel
Multiple Myeloma
FDA
Biomarin
Merck
molnupiravir
Looking to win back investor confidence, BioMarin preps for its ‘largest launch’
Endpoints
Thu, 10/28/21 - 10:47 am
Biomarin
Voxzogo
drug launches
achrondoplasia
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »